SCLX vs COLL vs AVDL vs PAHC vs SUPN

For growth investors, Avadel Pharmaceuticals plc (AVDL) is the stronger pick with 504.

8% revenue growth year-over-year, versus 8. 6% for Supernus Pharmaceuticals, Inc. (SUPN). Collegium Pharmaceutical, Inc. (COLL) offers the better valuation at 21. 8x trailing P/E (5. 1x forward), making it the more compelling value choice. Analysts rate Scilex Holding Company (SCLX) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Collegium Pharmaceutical, Inc.

(COLL) is the cheapest at 21. 8x versus Phibro Animal Health Corporation at 33. 6x. On forward P/E, Scilex Holding Company is actually cheaper at 2. 5x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Collegium Pharmaceutical, Inc. wins at 0. 28x versus Phibro Animal Health Corporation's 1. 75x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Avadel Pharmaceuticals plc (AVDL) delivered a total return of +167.

8%, compared to -97. 8% for Scilex Holding Company (SCLX). Over 10 years, the gap is even starker: SUPN returned +223. 7% versus SCLX's -97. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Avadel Pharmaceuticals plc (AVDL) is the lower-risk stock at 0.

19β versus Scilex Holding Company's 2. 30β — meaning SCLX is approximately 1128% more volatile than AVDL relative to the S&P 500. On balance sheet safety, Avadel Pharmaceuticals plc (AVDL) carries a lower debt/equity ratio of 2% versus 3% for Collegium Pharmaceutical, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Avadel Pharmaceuticals plc (AVDL) is pulling ahead at 504.

8% versus 8. 6% for Supernus Pharmaceuticals, Inc. (SUPN). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to -151. 5% for Supernus Pharmaceuticals, Inc.. Over a 3-year CAGR, SCLX leads at 21. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Collegium Pharmaceutical, Inc.

(COLL) is the more profitable company, earning 8. 1% net margin versus -128. 7% for Scilex Holding Company — meaning it keeps 8. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: COLL leads at 24. 0% versus -147. 4% for SCLX. At the gross margin level — before operating expenses — AVDL leads at 91. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Collegium Pharmaceutical, Inc. (COLL) is the more undervalued stock at a PEG of 0. 28x versus Phibro Animal Health Corporation's 1. 75x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Scilex Holding Company (SCLX) trades at 2. 5x forward P/E versus 28. 3x for Avadel Pharmaceuticals plc — 25. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for COLL: 53. 4% to $58. 00.

In this comparison, PAHC (1.

2% yield) pays a dividend. SCLX, COLL, AVDL, SUPN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Avadel Pharmaceuticals plc (AVDL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

19), +113. 0% 10Y return). Scilex Holding Company (SCLX) carries a higher beta of 2. 30 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AVDL: +113. 0%, SCLX: -97. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SCLX is a small-cap high-growth stock; COLL is a small-cap high-growth stock; AVDL is a small-cap high-growth stock; PAHC is a small-cap high-growth stock; SUPN is a small-cap quality compounder stock. PAHC pays a dividend while SCLX, COLL, AVDL, SUPN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.